Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Makoto Arai"'
Autor:
Hiroaki Kanzaki, Sadahisa Ogasawara, Jun Kato, Makoto Arai, Takamasa Ishino, Naoya Kato, Hirokazu Makishima, Masato Nakamura, Takayuki Kondo, K. Fujiwara, Masaru Wakatsuki, Shingo Nakamoto, Miyuki Nakagawa, Keita Ogawa, Ryoi Yoshida, Tomoko Saito, Kazufumi Kobayashi, Hiroshi Tsuji, Takafumi Sakuma, Eiichiro Suzuki, Akinobu Tawada, Naoto Fujita, Tetsuhiro Chiba, Keisuke Koroki, Naoya Kanogawa, Terunao Iwanaga, Ryo Nakagawa, Yoshihiko Ooka, Takashi Kaneko, Hidemi Unozawa, Soichiro Kiyono
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 2, Pp 1103-1110 (2021)
Macrovascular invasion (MVI), including portal vein tumor thrombosis (PVTT), is strongly associated with poor prognosis in patients with hepatocellular carcinoma (HCC). While recommended standard treatment for patients with advanced HCC is systemic t
Autor:
Hiroaki Kanzaki, Atsushi Iwama, Shingo Nakamoto, Susumu Maruta, Naoya Kato, Yoshihiko Ooka, Yoh Zen, Ryosuke Muroyama, Tatsuo Kanda, Hitoshi Maruyama, Masayuki Ohtsuka, Tomoko Saito, Tetsuhiro Chiba, Keisuke Koroki, Jun Kato, Naoya Kanogawa, Kengo Kanayama, Takahiro Maeda, Eiichiro Suzuki, Junjie Ao, Yuko Kusakabe, Ryo Nakagawa, Makoto Arai, Akinobu Tawada, Takayuki Kondo, Kazufumi Kobayashi, Naoya Mimura, Masato Nakamura, Shin Yasui, Soichiro Kiyono, Sadahisa Ogasawara
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports
Scientific Reports
FGF19/FGFR4 autocrine signaling is one of the main targets for multi-kinase inhibitors (MKIs). However, the molecular mechanisms underlying FGF19/FGFR4 signaling in the antitumor effects to MKIs in hepatocellular carcinoma (HCC) remain unclear. In th
Autor:
Hiroto Mizuta, Shuraku Son, Jun Miyata, Takuya Hayashi, Toshihiko Aso, Makoto Arai, Toshiya Murai, Masanari Itokawa, Kazuya Toriumi
Publikováno v:
Schizophrenia Research. 223:242-248
Carbonyl stress is a state caused by an increase in rich reactive carbonyl compounds (RCOs); RCOs facilitate the formation of advanced glycation end products (AGEs), which are associated with various age-related illnesses. Recently, enhanced carbonyl
Autor:
Kazuhiro Suzuki, Satoshi Usami, Yasuhiro Miyano, Makoto Arai, Kenichi Oshima, Akane Yoshikawa, Syudo Yamasaki, Shunya Takizawa, Yukihiro Nagase, Mitsuhiro Miyashita, Atsushi Imai, Akiko Kobori, Atsushi Nishida, Yasue Horiuchi, Masanari Itokawa, Kazuya Toriumi, Kazuhiro Niizato, Heii Arai
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 5, p e0251283 (2021)
PLoS ONE, Vol 16, Iss 5, p e0251283 (2021)
Advanced glycation end products play a key role in the pathophysiology of schizophrenia. Cognitive impairment is one of the central features of schizophrenia; however, the association between advanced glycation end products and cognitive impairment r
Autor:
Takashi Dan, Yo Ichi Ishida, Toshio Miyata, Yuki Ogasawara, Sakura Kasahara, Makoto Arai, Kazuya Toriumi, Shin Koike, Yosuke Kibune
Publikováno v:
Antioxidants, Vol 10, Iss 574, p 574 (2021)
Antioxidants
Volume 10
Issue 4
Antioxidants
Volume 10
Issue 4
Recent studies have shown that carbonyl stress is a causative factor of schizophrenia, categorized as carbonyl stress-related schizophrenia (CS-SCZ). However, the correlation between carbonyl stress and the pathogenesis of this disease is not well es
Autor:
Hidemi Unozawa, Norio Itokawa, Hideaki Mizumoto, Ei Itobayashi, Soichiro Kiyono, Eiichiro Suzuki, Kenji Ito, Takafumi Sakuma, Masanori Atsukawa, Masato Nakamura, Takayuki Kondo, Masamichi Obu, Takahiro Maeda, Hitoshi Maruyama, Tatsuo Kanda, Yoshihiro Koma, Hiroaki Kanzaki, Shingo Nakamoto, Masanori Inoue, Akinobu Tawada, Makoto Arai, Yotaro Iino, Naoto Fujita, Tomoko Saito, Yuki Haga, Nobuyuki Sugiura, Naoya Kato, Sadahisa Ogasawara, Kazufumi Kobayashi, Shinichiro Okabe, Terunao Iwanaga, Tomomi Okubo, Jun Kato, Susumu Maruta, Ryosaku Azemoto, Yoshihiko Ooka, Atsuyoshi Seki, Tetsuhiro Chiba, Keisuke Koroki, Naoya Kanogawa
Publikováno v:
Liver Cancer, Pp 1-12 (2021)
Liver Cancer
Liver Cancer
Background: There is no standard posttreatment for patients with advanced hepatocellular carcinoma (HCC) in whom lenvatinib therapy has failed. This study aimed to investigate rates of migration to posttreatment after lenvatinib and to explore candid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97113103eaa47fc8b55c1f99b30d82ca
https://www.karger.com/Article/FullText/515552
https://www.karger.com/Article/FullText/515552
Autor:
Masato Nakamura, Masamichi Obu, Kengo Kanayama, Masanori Inoue, Ryosaku Azemoto, Tatsuo Kanda, Shinichiro Okabe, Sadahisa Ogasawara, Yoshihiko Ooka, Makoto Arai, Atsuyoshi Seki, Hitoshi Maruyama, Norio Itokawa, Takahiro Maeda, Masayuki Yokoyama, Shin Yasui, Ei Itobayashi, Tomoko Saito, Eiichiro Suzuki, Yuki Haga, Naoya Kato, Nobuyuki Sugiura, Yuko Kusakabe, Masanori Atsukawa, Susumu Maruta, Shingo Nakamoto, Hideaki Mizumoto, Soichiro Kiyono, Kazufumi Kobayashi, Hiroaki Kanzaki, Akinobu Tawada, Tetsuhiro Chiba
Publikováno v:
Investigational New Drugs. 38:172-180
Background Conversion from sorafenib to regorafenib is primarily an evidence-based treatment strategy in patients with advanced hepatocellular carcinoma (HCC). This study aimed to assess the safety and efficacy of sequential therapy with sorafenib an
Autor:
Shin Koike, Masanobu Kano, Mai Asakura, Masanari Itokawa, Stefano Berto, Noriyoshi Usui, Mitsuhiro Miyashita, Makoto Arai, Takaki Watanabe, Kazuhiro Suzuki, Akane Yoshikawa, Yasue Horiuchi, Yuki Ogasawara, Yuki Sugaya, Kazuya Toriumi, Toshio Miyata, Genevieve Konopka, Takashi Dan
Methylglyoxal (MG) is a cytotoxicα-dicarbonyl byproduct of glycolysis. Our bodies have several bio-defense systems to detoxify MG, including an enzymatic system by glyoxalase (GLO) 1 and a scavenge system by vitamin B6 (VB6). We know a population of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e86c83c7de672da58be9178aa1bbe81
https://doi.org/10.1101/2020.07.08.192906
https://doi.org/10.1101/2020.07.08.192906
Autor:
Kazufumi Kobayashi, Ryosaku Azemoto, Eiichiro Suzuki, Masamichi Obu, Norio Itokawa, Tatsuo Kanda, Masanori Atsukawa, Yoshihiko Ooka, Takayuki Kondo, Naoya Kanogawa, Atsuyoshi Seki, Masato Nakamura, Akinobu Tawada, Tomoko Saito, Soichiro Kiyono, Sadahisa Ogasawara, Hitoshi Maruyama, Kengo Kanayama, Naoya Kato, Shinichiro Okabe, Yuki Haga, Hideaki Mizumoto, Susumu Maruta, Shingo Nakamoto, Nobuyuki Sugiura, Tetsuhiro Chiba, Makoto Arai, Keisuke Koroki, Hiroaki Kanzaki, Masanori Inoue, Ei Itobayashi
Publikováno v:
Liver Cancer, Pp 1-15 (2020)
Liver Cancer
Liver Cancer
Background: The present study aimed to assess the efficacy and safety of lenvatinib and verify the possibility of lenvatinib for the expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma (HCC) in real-world pra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85c7fd4c243d37f9886093b3111c2c3b
https://www.karger.com/Article/FullText/507022
https://www.karger.com/Article/FullText/507022
Autor:
Genevieve Konopka, Yuki Ogasawara, Mai Asakura, Kazuya Toriumi, Shin Koike, Kazuhiro Suzuki, Toshio Miyata, Stefano Berto, Hsiao Chun Lin, Mitsuhiro Miyashita, Makoto Arai, Akane Yoshikawa, Takaki Watanabe, Takashi Dan, Yasue Horiuchi, Masanobu Kano, Masanari Itokawa, Noriyoshi Usui, Yuki Sugaya, Kenichiro Nagahama
Publikováno v:
Redox Biology
Redox Biology, Vol 45, Iss, Pp 102057-(2021)
Redox Biology, Vol 45, Iss, Pp 102057-(2021)
Methylglyoxal (MG) is a reactive and cytotoxic α-dicarbonyl byproduct of glycolysis. Our bodies have several bio-defense systems to detoxify MG, including an enzymatic system by glyoxalase (GLO) 1 and GLO2. We identified a subtype of schizophrenia p